Triple-negative breast cancer: disease entity or title of convenience?
作者： Lisa Carey , Eric Winer , Giuseppe Viale , David Cameron , Luca Gianni
DOI: 10.1038/NRCLINONC.2010.154
关键词:
摘要: … that abnormalities of other members of the BRCA1 pathway lead to functional BRCA1 loss. … TNBC and BRCA1-associated and BRCA2-associated tumors. Loss of BRCA1 or BRCA2 is …
nature.com
elsevier.com
ed.ac.uk
researchgate.net 
sci-hub.se 参考文章(145)
P. D. Ryan, N. M. Tung, S. J. Isakoff, M. Golshan, A. Richardson, A. D. Corben, B. L. Smith, R. Gelman, E. P. Winer, J. E. Garber, Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy Journal of Clinical Oncology. ,vol. 27, pp. 551- 551 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.551
M Lund, JW Eley, RM O'Regan, SS Gabram, HI Saavedra, JM Liff, OW Brawley, PL Porter, Molecular differences between the triple negative tumors of African-American women and white women. Cancer Research. ,vol. 69, pp. 2087- ,(2009) , 10.1158/0008-5472.SABCS-2087
S. Kopetz, M. M. Mita, I. Mok, K. K. Sankhala, J. Moseley, B. M. Sherman, C. R. Bradley, A. W. Tolcher, First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors Journal of Clinical Oncology. ,vol. 26, pp. 3577- 3577 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.3577
J. J. Mahany, N. Lewis, E. I. Heath, P. M. LoRusso, M. M. Mita, J. Rodon, A. W. Tolcher, B. M. Sherman, C. R. Bradley, K. P. Papadopoulos, A phase IB study evaluating BSI-201 in combination with chemotherapy in subjects with advanced solid tumors Journal of Clinical Oncology. ,vol. 26, pp. 3579- 3579 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.3579
S. Delaloge, K. L. Tedesco, J. Blum, A. Gonçalves, J. Lubinski, N. Efrat, C. Osborne, C. Lebedinsky, J. C. Tercero, F. A. Holmes, Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts) Journal of Clinical Oncology. ,vol. 27, pp. 1010- 1010 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.1010
H. Nechushtan, H. Steinberg, T. Peretz, Prelimenary results of a phase I/II of a combination of cetuximab and taxane for triple negative breast cancer patients Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.E12018
S Vukelja, D Weckstein, J O’Shaughnessy, Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer ,(2007)
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler, Andrew Wardley, Gillian Mitchell, Helena Earl, Mark Wickens, James Carmichael, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer The Lancet. ,vol. 376, pp. 235- 244 ,(2010) , 10.1016/S0140-6736(10)60892-6
S. Nicholas Agoff, Paul E. Swanson, Hannah Linden, Stephen E. Hawes, Thomas J. Lawton, Androgen Receptor Expression in Estrogen Receptor–Negative Breast Cancer American Journal of Clinical Pathology. ,vol. 120, pp. 725- 731 ,(2003) , 10.1309/42F00D0DJD0J5EDT
Jose Palacios, N Benito, A Pizarro, Asuncion Suárez, Jesus Espada, A Cano, C Gamallo, Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features. American Journal of Pathology. ,vol. 146, pp. 605- 612 ,(1995)